Journal article
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
A Pereira-Salgado, A Anton, F Franchini, RK Mahar, EM Kwan, S Wong, J Shapiro, A Weickhardt, AA Azad, L Spain, A Gunjur, J Torres, P Parente, F Parnis, J Goh, C Steer, S Brown, P Gibbs, B Tran, M IJzerman
Expert Review of Pharmacoeconomics and Outcomes Research | TAYLOR & FRANCIS LTD | Published : 2023
Abstract
Introduction: Health economic outcomes of real-world treatment sequencing of androgen receptor-targeted agents (ARTA) and docetaxel (DOC) remain unclear. Material and Methods: Data from the electronic Castration-resistant Prostate cancer Australian Database (ePAD) were analyzed including median overall survival (mOS) and median time-to-treatment failure (mTTF). Mean total costs (mTC) and incremental cost-effectiveness ratios (ICER) of treatment sequences were estimated using the average sample method and Zhao and Tian estimator. Results: Of 752 men, 441 received ARTA, 194 DOC, and 175 both sequentially. Of participants treated with both, first-line DOC followed by ARTA was the more common se..
View full abstractGrants
Funding Acknowledgements
This research project did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sector. The ePAD clinical registry received financial support from Amgen, AstraZeneca, Astellas, and Janssen during the period of this study. These pharmaceutical companies were not involved in the study design, data analysis, or production of this manuscript.